...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Comparing the Efficacy of DeVIC Therapy and High-dose Methotrexate Monotherapy with Whole-brain Radiation Therapy for Newly-diagnosed Primary Central Nervous System Lymphoma: A Single Institution Study
【24h】

Comparing the Efficacy of DeVIC Therapy and High-dose Methotrexate Monotherapy with Whole-brain Radiation Therapy for Newly-diagnosed Primary Central Nervous System Lymphoma: A Single Institution Study

机译：比较患者治疗和高剂量甲氨蝶呤单药治疗全脑放射治疗新诊断的原发性神经系统淋巴瘤的疗效：单一机构研究

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background/Aim: In the current study, we aimed to compare DeVIC (dexamethasone, etoposide, ifosfamide and carboplatin) chemotherapy with high-dose methotrexate (HD-MTX) monotherapy plus whole-brain radiation therapy (WBRT) for newly-diagnosed primary central nervous system lymphoma (PCNSL), in terms of their efficacies and tolerability. Patients and Methods: A total of 21 consecutive patients with PCNSL were treated with DeVIC therapy and WBRT, between 2002 and 2010. From 2010 to 2014, 14 consecutive patients with PCNSL were treated with HD-MTX followed by WBRT. Results: Overall response rates of complete and partial response for initial chemotherapy were significantly better with DeVIC therapy (95.2%) than with HD-MTX monotherapy (50%). Furthermore, one-year and two-year progression-free survival (PFS) rates were better in the DeVIC cohort than in the HD-MTX cohort. DeVIC therapy yielded higher early response rates, longer PFS, and manageable adverse events, and may be potentially better for the treatment of cases that are refractory to MTX-based therapy. Conclusion: Our retrospective clinical study revealed that DeVIC therapy is comparable with that of HD-MTX monotherapy plus WBRT, for newly diagnosed PCNSL.
机译：背景/目的：在目前的研究中，我们旨在将具有高剂量甲氨蝶呤（HD-MTX）单疗法加上全脑放射治疗（WBRT）进行新诊断的原发性中央的文献（地塞米松，依托肽，IFOSFAMIDE和CARBOPLATIN）化疗进行比较神经系统淋巴瘤（PCNSL），在它们的效率和耐受性方面。患者和方法：2002年至2010年间，共有21例连续21例患有的PCNSL患者和WBRT治疗。从2010年到2014年，将连续14例PCNSL患者用HD-MTX进行处理，然后进行WBRT。结果：初始化疗的完整和部分响应的总体响应率明显更好，具有比HD-MTX单药治疗（50％）的疗法治疗更好（95.2％）。此外，在HD-MTX队列中，一年和两年的无进展生存期（PFS）率更好。变性疗法产生更高的早期响应率，更长的PFS和可管理的不良事件，并且可能对治疗难治性的基于MTX的治疗的病例可能会更好。结论：我们的回顾性临床研究表明，对于新诊断的PCNSL，Demication疗法与HD-MTX单药治疗加WBRT相当。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号